Unknown

Dataset Information

0

Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.

ABSTRACT: INTRODUCTION:The safety and efficacy of exenatide once weekly (EQW) is overall well established. EQW is primarily renally eliminated. In this study, the efficacy and renal and gastrointestinal tolerability of EQW were summarised in participants with type 2 diabetes and chronic kidney disease stage 3 (CKD3; moderate renal impairment; estimated glomerular filtration rate [eGFR]???30 to?

SUBMITTER: Guja C 

PROVIDER: S-EPMC7324446 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.

Guja Cristian C   Frías Juan P JP   Suchower Lisa L   Hardy Elise E   Marr Galina G   Sjöström C David CD   Jabbour Serge A SA  

Diabetes therapy : research, treatment and education of diabetes and related disorders 20200418 7

<h4>Introduction</h4>The safety and efficacy of exenatide once weekly (EQW) is overall well established. EQW is primarily renally eliminated. In this study, the efficacy and renal and gastrointestinal tolerability of EQW were summarised in participants with type 2 diabetes and chronic kidney disease stage 3 (CKD3; moderate renal impairment; estimated glomerular filtration rate [eGFR] ≥ 30 to < 60 mL/min/1.73 m<sup>2</sup>) or CKD stage 2 (CKD2; mild renal impairment; eGFR ≥ 60 to < 90 mL/min/1.7  ...[more]

Similar Datasets

Unknown Efficacy and safety of once-weekly exenatide after switching from twice-daily exenatide in patients with type 2 diabetes.
| S-EPMC7078076 | biostudies-literature
Unknown A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes.
| S-EPMC5565650 | biostudies-other
Unknown Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks.
| S-EPMC3308312 | biostudies-literature
Unknown Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
| S-EPMC5724491 | biostudies-literature
Unknown Emerging utility of once-weekly exenatide in patients with type 2 diabetes.
| S-EPMC4621218 | biostudies-literature
Unknown Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
| S-EPMC6150435 | biostudies-other
Unknown Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.
| S-EPMC4445788 | biostudies-literature
Unknown Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
| S-EPMC5485171 | biostudies-literature
Unknown Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
| S-EPMC5969323 | biostudies-literature
Unknown Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.
| S-EPMC5813234 | biostudies-literature